Results 131 to 140 of about 490,902 (326)
Toward Wireless Implantable Robotic Systems Driven by Magnetic Field for Personalized Therapy
Robotic materials are playing an increasingly vital role in enabling sensing and actuation at small scales. This perspective highlights recent advances in magnetic materials and magnetically actuated devices for wireless sensing, actuation, and energy harvesting toward implantable robotic systems for closed‐loop therapy.
Yusheng Wang, Ruijian Ge, Xiaoguang Dong
wiley +1 more source
Introduction: Biologic disease-modifying anti-rheumatic drugs (bDMARDS) are increasingly used in clinical practice for a variety of conditions. Due to concerns surrounding persistence of drug levels and resulting immunosuppression, current case reports ...
Angela Berkhout +2 more
doaj +1 more source
Durability of Soft Pneumatic Actuators: A Review and Benchmarking Protocol
Lack of durability is a key challenge hindering the broad scale adoption of soft pneumatic actuators (SPAs) in automation industries. This review provides a comprehensive overview of existing research on SPA durability, introduces a standardized durability benchmarking protocol to consolidate the testing of SPAs, and outlines promising directions for ...
Dickson Chiu Yu Wong +2 more
wiley +1 more source
ABSTRACT Cuproptosis, an emerging form of programmed cell death, is capable of inducing mitochondrial dysfunction. Moreover, the PI3K‐AKT‐mTOR signaling pathway contributes to tumor cell progression by reprogramming mitochondrial morphology and function.
Lei Wu +10 more
wiley +1 more source
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by hemolytic anemia, bone marrow failure, and thrombosis. Until recently, the complement inhibitor, eculizumab, was the only United States Food and Drug Administration ...
Robert M. Stern, Nathan T. Connell
doaj +1 more source
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. [PDF]
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose-escalation study of tipifarnib, an oral FT inhibitor, in patients with relapsed, refractory or ...
Forman, SJ +13 more
core
Optimized Treatment Schedules for Chronic Myeloid Leukemia
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +3 more sources
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source
While the majority of people with cocaine use disorders (CUD) also co-use tobacco/nicotine, most preclinical cocaine research does not include nicotine.
Mia I. Allen +6 more
doaj +1 more source
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang +13 more
wiley +1 more source

